View Author
patient cancer sarcoma survival lymphopenia treatment group study tissue sarcoma tissue factor prognostic lymphocyte response count cycle grade toxicity tumor lymphoma chemotherapy research model analysis non-gist group trial metastatic disease progression-free survival month metastase table breast progression lymphocyte count lymphocyte counts liver metastases european non-gist gist group agent multivariate analysis prognostic factors prognostic factor bone sarcoma group grade 3 neutropenia brostallicin multivariate level tumour carcinoma serum liver article progression-free oncol <0.0001 phase characteristic presence result series therapy lymphocytes onlinefirst value criteria univariate analysis american cancer research cancer research www.aacrjournals.org prognostic value activity association univariate status blood prognosis cancer patients
2 Most Recent Publications
|
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas
(Article)
Ray-Coquard, I. Cropet, C. Guastalla, J.P. Bachelot, T. Perol, D. Chabaud, S. Hogendoorn, P.C.W. Cassier, P. Dufresne, A. Blay, J-Y. Glabbeke, M.M.B. van Sebban, C. Cesne, A. le Judson, I.R. Tredan, O. Verweij, J. Biron, P. Labidi, I. |
2009-07-01
|
|
Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: A phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
(Article)
Leahy, M. Ray-Coquard, I. Judson, I.R. Blay, J-Y. Verweij, J. Cesne, A. le Duffaud, F. Hogendoorn, P.C.W. Fowst, C. Balincourt, C. de Paola, E.D. di Glabbeke, M.M.B. van |
2007-01-01
|
